Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vitasora Health Limited (VHL.AX)
Melbourne, VIC, AU
Headquartered in Melbourne, Australia, Vitasora Health Limited specializes in the research, development, and market introduction of medical devices across Australia and the United States. The company's portfolio also includes the creation of mobile health applications. Notably, the firm, previously known as Respiri Limited, officially rebranded as Vitasora Health Limited in April 2025.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -28.57% | -37.50% | -58.33% | -61.54% | -58.33% | -76.19% | -71.43% | -88.89% | -67.74% | -99.12% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+547.8% ★ Q4'24: +15,588.8% (vs Q4'22)
-
EPS growth Medical - Healthcare Information Services: +43.1%+2.8% Q4'24: +9.1% (vs Q4'22)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-1,576.6% Q4'24: -269.2% (vs Q4'22)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-1,546.1% Q4'24: -235.7% (vs Q4'22)
-
ROIC Medical - Healthcare Information Services: +5.2%-225.1% Q4'24: -398.4% (vs Q4'22)
-
Share dilution Medical - Healthcare Information Services: -0.1%+26.2% Q4'24: +55.4% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-0.18× Q4'24: -0.01× (vs Q4'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
70.5K
est: 6.64M (-98.9%)
|
456.9K
est: 4.90M (-90.7%)
|
6.30M
est.
|
11.80M
11.80M – 11.80M
+87.3% YoY
|
18.70M
18.70M – 18.70M
+58.5% YoY
|
| EBITDA |
-5.68M
est: -6.64M (+14.5%)
|
-7.00M
est: -4.90M (-42.9%)
|
-6.30M
est.
|
-11.80M
-11.80M – -11.80M
-87.3% YoY
|
-18.70M
-18.70M – -18.70M
-58.5% YoY
|
| EBIT |
-5.76M
est: -6.64M (+13.3%)
|
-7.06M
est: -4.90M (-44.2%)
|
-6.30M
est.
|
-11.80M
-11.80M – -11.80M
-87.3% YoY
|
-18.70M
-18.70M – -18.70M
-58.5% YoY
|
| Net Income |
-5.78M
est: -2.04M (-183.8%)
|
-7.13M
est: -5.09M (-40.1%)
|
-5.09M
est.
|
-1.02M
-1.02M – -1.02M
+80.0% YoY
|
2.04M
2.04M – 2.04M
+300.0% YoY
|
| SGA |
5.04M
est: 183.35M (-97.2%)
|
6.94M
est: 135.23M (-94.9%)
|
173.86M
est.
|
325.65M
325.65M – 325.65M
+87.3% YoY
|
516.06M
516.06M – 516.06M
+58.5% YoY
|
| EPS |
-0.01
est: 0.00 (-260.0%)
|
-0.01
est: -0.01 (-40.0%)
|
-0.01
est.
|
0.00
0.00 – 0.00
+80.0% YoY
|
0.00
0.00 – 0.00
+300.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marjan Mikel | Chief Executive Officer, MD & Executive Director | 511.2K | male |
| Peter Hildebrandt | Chief Operations Officer | 288.1K | male |
| Nicholas Smedley | Executive Chairman | 245.5K | male |
| Samaneh Sarraf Shirazi | Chief Research Officer | 195.2K | — |
| Simon Godfrey | Medical & Scientific Advisor | 191.6K | male |
| Noam Gavriely | Medical & Scientific Advisor | 191.6K | — |
| William Sigsbee | Head of US Operations & Chief Commercial Officer for the US market | — | male |
| Shelby Coleman | Joint Company Secretary | — | female |
| Charly Duffy | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VHL.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
